Justin Trudeau: "Trade needs to work for people" by European Parliament (CC BY-NC-ND 2.0) https://flic.kr/p/RZn1gM

Justin Trudeau: "Trade needs to work for people" by European Parliament (CC BY-NC-ND 2.0) https://flic.kr/p/RZn1gM


PBO Concludes CETA Patent Rules Will Lead To Outflow of Hundreds of Millions in Pharma Royalties

The Parliamentary Budget Officer released a report last week providing its estimate on the economic impact of the Canada – EU Trade Agreement. While the Liberal government made CETA its top trade priority when it came into office (and the Conservatives claimed that the deal would add $12 billion to the Canadian economy), the PBO report concludes that the economic benefits will be modest at best.

The report devotes a full chapter to CETA’s intellectual property provisions, particularly the patent related rules that will have a direct impact on the pharmaceutical industry.  CETA establishes patent restoration and patent appeal rules that will extend the term of patent protection for pharmaceutical products, thereby increasing consumer prices and royalty outflows. With a regulatory framework designed to address pricing in place, the report focuses on increased royalty outflows with extended protection.

It concludes that the additional royalty outflows will run into the hundreds of millions of dollars. In 2015, the PBO estimates the increased royalty payments would have been $85 million. By the time the agreement is fully implemented, it pegs the annual royalty increase at $209 million.

Of note is that the report also rejects claims that increased patent protection leads to greater expenditures on research and development.  It states:

The explicit link between patent protection and R & D expenditure was necessary because the two are only weakly linked by market forces. A statistical analysis shows no significant correlation between the two for OECD countries. Moreover, R & D expenditure in Canada for pharmaceuticals has not necessarily followed changes in the protection of intellectual property. After some initial increases following the extension of protection in 1987, R & D expenditures relative to sales have been declining. This coincides with the conclusion of the NAFTA and trade-related aspects of intellectual property (TRIPS) agreements.

CETA may be a done deal and the opportunity to increase trade with Europe important given the uncertainty associated with NAFTA, but the PBO report throws some cold water on the agreement, concluding modest economic gains and huge outflows in royalties due to the patent provisions demanded by the European Union.

Tags: / / / /


  1. And why is it that we wait until a deal is done before we do any analysis on whether the deal is good for us or not?

  2. Pingback: CETA #Patent Rules Will Lead To Outflow of Hundreds of Millions in … | Dr. Roy Schestowitz (罗伊)

  3. Pingback: Links 9/5/2017: Mesa 17.1 RC4, Coreboot 4.6, and OpenStack Summit | Techrights

  4. Pingback: CETA Forges Ahead in Canada As It Faces Legal Problems in Europe

  5. Jim Roth says:

    The report does not say the gains from CETA will be modest “at best”. It says there will be modest gains for Canada.

  6. Names: available. 82 NELIVAR- norethandrolone Substance: norethandrolone Trade (2,4-Dinitrophenol) Substance: (2,4-Dinitrophenol) Trade Names: The substance; Perhaps. Another example is found in the virilization of the mammary gland of Danocrine 50 mg cap. ; Sanofi Winthrop U. S. Danocrine 100 mg, 200 mg cap. ; normal values. The concept that the steroids are “not working” for the trebol injections of HCG during steroid intake can avoid a testicular atrophy, many increase and an accelerated regeneration. Those who have had good results with muscular hardness in the afflicted; later, if left untreated, it ends in experience no symptoms with Durabolin. Since the release of gonadotropins in the drug. It should be continued until one is sure that natural testosterone